1. Goss, C.H., Ratjen, F.: Update in cystic fibrosis 2012. Am. J. Respir. Crit. Care Med. 187, 915–919 (2013).
http://www.atsjournals.org/doi/abs/10.1164/rccm.201301-0184UP?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
2. Lomas, P.: Enhancing adherence to inhaled therapies in cysic fibrosis. Ther. Adv. Respir. Dis. 8, 39–47 (2014).
http://tar.sagepub.com/content/8/2/39.long
3. Klimeš, J., Doležal, T., Kubáčková, K., Turnovec, M., Macek Jr., M.: Health-economic aspects of cystic fibrosis screening and therapy. Eur. Respir. Soc. monogr. 64, 304–319 (2014)
4. Gu, Y., Pérez-García, S., Massie, J., van Gool, K.: Cost of care for cystic fibrosis: an investigation of cost determinants using national registry data. Eur. J. Health Econ. 16, 709–717 (2015).
http://link.springer.com/article/10.1007%2Fs10198-014-0621-5
5. De Boeck, K., Zolin, A., Cuppens, H., Olesen, H.V., Viviani, L.: The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. J. Cyst. Fibros. 13, 403–409 (2014).
http://www.cysticfibrosisjournal.com/article/S1569-1993(13)00228-2/abstract